Advanced

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

Antoniou, A C; Pharoah, P D P; Narod, S; Risch, H A; Eyfjord, J E; Hopper, J L; Olsson, Håkan LU ; Johannsson, O; Borg, Åke LU and Pasini, B, et al. (2005) In Journal of Medical Genetics 42(7). p.602-603
Abstract
A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutations to be higher than previously published estimates derived from population based studies. In an attempt to confirm this, the breast and ovarian cancer risks associated with the three Ashkenazi founder mutations were estimated using families included in a previous meta-analysis of populatrion based studies. The estimated breast cancer risks for each of the founder BRCA1 and BRCA2 mutations were similar to the corresponding estimates based on all BRCA1 or BRCA2 mutations in the meta-analysis. These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population.
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Medical Genetics
volume
42
issue
7
pages
602 - 603
publisher
BMJ Publishing Group
external identifiers
  • wos:000230235800012
  • pmid:15994883
  • scopus:22244467729
ISSN
0022-2593
DOI
10.1136/jmg.2004.024133
language
English
LU publication?
yes
id
b91dac3e-719d-4ff7-9615-35c011debc41 (old id 233800)
date added to LUP
2007-08-06 13:44:18
date last changed
2017-11-19 04:11:16
@article{b91dac3e-719d-4ff7-9615-35c011debc41,
  abstract     = {A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutations to be higher than previously published estimates derived from population based studies. In an attempt to confirm this, the breast and ovarian cancer risks associated with the three Ashkenazi founder mutations were estimated using families included in a previous meta-analysis of populatrion based studies. The estimated breast cancer risks for each of the founder BRCA1 and BRCA2 mutations were similar to the corresponding estimates based on all BRCA1 or BRCA2 mutations in the meta-analysis. These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population.},
  author       = {Antoniou, A C and Pharoah, P D P and Narod, S and Risch, H A and Eyfjord, J E and Hopper, J L and Olsson, Håkan and Johannsson, O and Borg, Åke and Pasini, B and Radice, P and Manoukian, S and Eccles, D M and Tang, N and Olah, E and Anton-Culver, H and Warner, E and Lubinski, J and Gronwald, J and Gorski, B and Tulinius, H and Thorlacius, S and Eerola, H and Nevanlinna, H and Syrjakoski, K and Kallioniemi, O P and Thompson, D and Evans, C and Peto, J and Lalloo, F and Evans, D G and Easton, D F},
  issn         = {0022-2593},
  language     = {eng},
  number       = {7},
  pages        = {602--603},
  publisher    = {BMJ Publishing Group},
  series       = {Journal of Medical Genetics},
  title        = {Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies},
  url          = {http://dx.doi.org/10.1136/jmg.2004.024133},
  volume       = {42},
  year         = {2005},
}